Pharmacokinetic studies have recently become an integral aspect of chemopreventive drug development. Early trials, based largely on epidemiologic studies, used drug doses and schedules derived empirically. Pharmacokinetic issues of chemopreventive drug development and trial design, conduct, and interpretation are illustrated with examples of retinoid and beta-carotene studies from the Arizona Cancer Center Chemoprevention Program.
|Original language||English (US)|
|Number of pages||3|
|State||Published - Dec 1 1991|
ASJC Scopus subject areas
- Cancer Research